ResMed Q1 2022 Earnings Report
Key Takeaways
ResMed Inc. reported a 20% increase in revenue to $904.0 million and a 21% increase in operating profit for the first quarter of fiscal year 2022. The company's performance was driven by high demand for sleep and respiratory care products and steady growth in its software-as-a-service business, despite ongoing supply chain challenges.
Revenue increased by 20% to $904.0 million, or 19% on a constant currency basis.
Diluted earnings per share were $1.39, while non-GAAP diluted earnings per share reached $1.51.
Income from operations increased by 21%, with non-GAAP operating profit up by 18%.
Software as a Service revenue increased by 6%, driven by continued growth in resupply service offerings and stabilizing patient flow in out-of-hospital care settings.
ResMed
ResMed
ResMed Revenue by Segment
ResMed Revenue by Geographic Location
Forward Guidance
No specific forward guidance was provided in the earnings report.
Revenue & Expenses
Visualization of income flow from segment revenue to net income